Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 11, 2011 - Issue sup4
Submit an article Journal homepage
328
Views
14
CrossRef citations to date
0
Altmetric
Symposium Paper

Pathophysiology, assessment and management of multiple sclerosis spasticity: an update

Judith Haas Judisches Krankenhaus Berlin, Abteilung fur Neurologie, Heinz-Galinski Str. 1, 13347, Berlin, Germany. [email protected]
Pages 3-8 | Published online: 09 Jan 2014

References

  • Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med.343(13), 938–952 (2000).
  • Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med.338(5), 278–285 (1998).
  • Pugliatti M, Rosati G, Carton H et al. The epidemiology of multiple sclerosis in Europe. Eur. J. Neurol.13, 700–722 (2006).
  • Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol. Assess.6(10), 1–73 (2002).
  • Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. Neurorehabil. Neural Repair17, 66–70 (2003).
  • Stevenson VL. Rehabilitation in practice: spasticity management. Clin. Rehabil.24, 293–304 (2010).
  • Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler.10(5), 589–595 (2004).
  • Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM97(10), 671–676 (2004).
  • Springhouse. Handbook of Signs and Symptoms (3rd Edition). Lippincott Williams & Wilkins, PA, USA (2005).
  • Hutchinson B. What is spasticity and what causes it? MS in Focus12, 6–8 (2008).
  • Lindquist S, Bodammer N, Kaufmann J et al. Histopathology and serial, multimodal magnetic resonance imaging in a multiple sclerosis variant. Mult. Scler.13(4), 471–482 (2007).
  • Ashworth B: Preliminary trial of carisoprodol in multiple sclerosis. Practitioner192, 540–542 (1964).
  • Bohannon RW, Smith MB. Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys. Ther.67, 206–207 (1987).
  • Farrar JT, Troxel A, Stott CG, Duncombe P. The validity, reliability and clinical importance of changes in spasticity severity measured on a 0–10 numerical rating scale. J. Neurol.254(Suppl. 3), 21 (2007).
  • Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0–10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin. Ther.30(5), 974–985 (2008).
  • Collin C, Davies P, Mutiboko IK et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol.14, 290–296 (2007).
  • Hobart JC, Riazi A, Thompson AJ et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain129(Pt 1), 224–234 (2006).
  • Bavikatte G, Gaber T. Approach to spasticity in general practice. Br. J. Med. Pract.2(3), 29–34 (2009).
  • Shakespeare D, Boggild M, Young CA. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev.4, CD001332 (2003).
  • Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol. Assess.7(40), iii, ix-x, 1–111 (2003).
  • Henze T, Rieckmann P, Toyka KV; Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur. Neurol.56(2), 78–105 (2006).
  • Stuke K, Flachenecker P, Zettl UK et al. Symptomatology of MS: results from the German MS Registry. J. Neurol.256(11), 1932–1935 (2009).
  • Brichetto G, Messmer Uccelli M, Mancardi GL, Solaro C. Symptomatic medication use in multiple sclerosis. Mult. Scler.9(5), 458–460 (2003).
  • Flachenecker P, Khil L, Bergmann S et al. Development and pilot phase of a European MS register. J. Neurol.257(10), 1620–1627 (2010).
  • Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology62(11), 2098–2100 (2004).
  • Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult. Scler.12(5), 646–651 (2006).
  • Martínez-Rodríguez JE, Munteis E, Carreño M et al. Cannabis use in Spanish patients with multiple sclerosis: fulfilment of patients’ expectations? J. Neurol. Sci.273(1–2), 103–107 (2008).

Website

  • European Medicines Agency. Guideline on clinical medicinal products intended for the treatment of neuropathic pain, January 2007 www.emea.europa.eu (Accessed December 2010)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.